SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

SANES

10.788

+0.77%↑

BBVA

20.23

+1.89%↑

BNP

93.16

+1.66%↑

CABK

11.685

+2.28%↑

INGA

26.82

+1.3%↑

Home・Aktien・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Geschlossen

BrancheFinanzen

181.4 3.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

181.4

Max

183.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	41M 88M
Verkäufe	-11M 762M
KGV Branchendurchschnitt	62.036 58.051
EPS	1.17
Gewinnspanne	11.569
Angestellte	10,456
EBITDA	26M 225M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+33.37% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	23. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.6B 17B
Vorheriger Eröffnungskurs	177.86
Vorheriger Schlusskurs	181.4

Nachrichtenstimmung

By Acuity

21%

79%

30 / 438 Ranking in Finance

Sartorius Stedim Biotech. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Sartorius Stedim Biotech. Prognose

Kursziel

By TipRanks

33.37% Vorteil

12-Monats-Prognose

Durchschnitt 233 EUR 33.37%

Hoch 262 EUR

Tief 210 EUR

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sartorius Stedim Biotech. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Sartorius Stedim Biotech. – Dist abgegeben haben.

Stimmung

By Acuity

30 / 438 Ranking in Finanzen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.